Publication | Closed Access

Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer

Oncolytic VirotherapyEngineered Interfering LncrnaImmune Checkpoint InhibitorBreast CancerTriple-negative Breast CancerTumor SuppressorRadiation OncologyMedicineCell BiologyViral OncologyCancer-associated Virus